Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Agios Pharmaceuticals Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 3 examiners and 3 art units, so each matter follows a separate examination path.
KIFLE, BRUCK handles 1 pending matter and is the busiest examiner. Counsel should use application-specific responses while maintaining consistent technical and claim positions across the pharmaceutical portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288888 | METHODS FOR TITRATING MITAPIVAT | RZECZYCKI, PHILLIP MATTHEW | 22d |
| 18882884 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | KIFLE, BRUCK | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18882884 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | KIFLE, BRUCK | 1624 | DP | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18288888 | METHODS FOR TITRATING MITAPIVAT | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Final Rejection | 22d | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAgios Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bruck Kifle has the most, with 1 of Agios Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
